Logo image of ATRA

ATARA BIOTHERAPEUTICS INC (ATRA) Stock Fundamental Analysis

USA - NASDAQ:ATRA - US0465132068 - Common Stock

13.95 USD
-0.31 (-2.17%)
Last: 9/25/2025, 1:57:48 PM
Fundamental Rating

3

Taking everything into account, ATRA scores 3 out of 10 in our fundamental rating. ATRA was compared to 538 industry peers in the Biotechnology industry. There are concerns on the financial health of ATRA while its profitability can be described as average. While showing a medium growth rate, ATRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ATRA had negative earnings in the past year.
ATRA had a negative operating cash flow in the past year.
In the past 5 years ATRA always reported negative net income.
ATRA had a negative operating cash flow in each of the past 5 years.
ATRA Yearly Net Income VS EBIT VS OCF VS FCFATRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With an excellent Return On Assets value of 15.70%, ATRA belongs to the best of the industry, outperforming 95.91% of the companies in the same industry.
ATRA's Return On Invested Capital of 83.02% is amongst the best of the industry. ATRA outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 15.7%
ROE N/A
ROIC 83.02%
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRA Yearly ROA, ROE, ROICATRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

Looking at the Profit Margin, with a value of 3.07%, ATRA belongs to the top of the industry, outperforming 90.71% of the companies in the same industry.
The Operating Margin of ATRA (12.44%) is better than 92.94% of its industry peers.
Looking at the Gross Margin, with a value of 81.24%, ATRA belongs to the top of the industry, outperforming 84.94% of the companies in the same industry.
Industry RankSector Rank
OM 12.44%
PM (TTM) 3.07%
GM 81.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRA Yearly Profit, Operating, Gross MarginsATRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ATRA is creating value.
The number of shares outstanding for ATRA has been increased compared to 1 year ago.
The number of shares outstanding for ATRA has been reduced compared to 5 years ago.
ATRA has a worse debt/assets ratio than last year.
ATRA Yearly Shares OutstandingATRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATRA Yearly Total Debt VS Total AssetsATRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

ATRA has an Altman-Z score of -68.03. This is a bad value and indicates that ATRA is not financially healthy and even has some risk of bankruptcy.
ATRA has a Altman-Z score of -68.03. This is amonst the worse of the industry: ATRA underperforms 94.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -68.03
ROIC/WACC9.53
WACC8.71%
ATRA Yearly LT Debt VS Equity VS FCFATRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

ATRA has a Current Ratio of 1.70. This is a normal value and indicates that ATRA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ATRA (1.70) is worse than 79.18% of its industry peers.
A Quick Ratio of 1.70 indicates that ATRA should not have too much problems paying its short term obligations.
ATRA's Quick ratio of 1.70 is on the low side compared to the rest of the industry. ATRA is outperformed by 78.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.7
ATRA Yearly Current Assets VS Current LiabilitesATRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

ATRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.91%, which is quite impressive.
Looking at the last year, ATRA shows a very strong growth in Revenue. The Revenue has grown by 202.40%.
Measured over the past years, ATRA shows a very strong growth in Revenue. The Revenue has been growing by 85.07% on average per year.
EPS 1Y (TTM)98.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.13%
Revenue 1Y (TTM)202.4%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-38.63%

3.2 Future

ATRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.75% yearly.
The Revenue is expected to grow by 5.91% on average over the next years.
EPS Next Y91.7%
EPS Next 2Y38.41%
EPS Next 3Y20.87%
EPS Next 5Y18.75%
Revenue Next Year3.31%
Revenue Next 2Y-32.22%
Revenue Next 3Y-65.7%
Revenue Next 5Y5.91%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ATRA Yearly Revenue VS EstimatesATRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ATRA Yearly EPS VS EstimatesATRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATRA Price Earnings VS Forward Price EarningsATRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

ATRA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ATRA is cheaper than 98.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 4.04
ATRA Per share dataATRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

ATRA's earnings are expected to grow with 20.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.41%
EPS Next 3Y20.87%

More info and screens

0

5. Dividend

5.1 Amount

ATRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (9/25/2025, 1:57:48 PM)

13.95

-0.31 (-2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10
Inst Owners51.11%
Inst Owner Change-13.54%
Ins Owners3.06%
Ins Owner Change1.59%
Market Cap97.93M
Analysts80
Price Target16.83 (20.65%)
Short Float %3.14%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)206.91%
Min EPS beat(2)140.49%
Max EPS beat(2)273.33%
EPS beat(4)3
Avg EPS beat(4)108.14%
Min EPS beat(4)-48.64%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)42.3%
EPS beat(12)6
Avg EPS beat(12)18.14%
EPS beat(16)9
Avg EPS beat(16)16.65%
Revenue beat(2)2
Avg Revenue beat(2)866.25%
Min Revenue beat(2)134.43%
Max Revenue beat(2)1598.08%
Revenue beat(4)4
Avg Revenue beat(4)453.06%
Min Revenue beat(4)12.04%
Max Revenue beat(4)1598.08%
Revenue beat(8)5
Avg Revenue beat(8)208.9%
Revenue beat(12)5
Avg Revenue beat(12)115.29%
Revenue beat(16)8
Avg Revenue beat(16)126.52%
PT rev (1m)-2.94%
PT rev (3m)7.61%
EPS NQ rev (1m)-5.35%
EPS NQ rev (3m)32.97%
EPS NY rev (1m)0%
EPS NY rev (3m)78.97%
Revenue NQ rev (1m)-3.58%
Revenue NQ rev (3m)-76.03%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)246.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.52
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 4.04
EPS(TTM)-0.43
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-9.12
FCFYN/A
OCF(TTM)-9.1
OCFYN/A
SpS26.88
BVpS-4.99
TBVpS-4.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 15.7%
ROE N/A
ROCE 105.09%
ROIC 83.02%
ROICexc 115908%
ROICexgc 115908%
OM 12.44%
PM (TTM) 3.07%
GM 81.24%
FCFM N/A
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover5.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 1.44
Cap/Depr 2.06%
Cap/Sales 0.05%
Interest Coverage 52.87
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.7
Quick Ratio 1.7
Altman-Z -68.03
F-Score5
WACC8.71%
ROIC/WACC9.53
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.13%
EPS Next Y91.7%
EPS Next 2Y38.41%
EPS Next 3Y20.87%
EPS Next 5Y18.75%
Revenue 1Y (TTM)202.4%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-38.63%
Revenue Next Year3.31%
Revenue Next 2Y-32.22%
Revenue Next 3Y-65.7%
Revenue Next 5Y5.91%
EBIT growth 1Y114.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.24%
EBIT Next 3Y15.72%
EBIT Next 5Y-3.99%
FCF growth 1Y70.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.02%
OCF growth 3YN/A
OCF growth 5YN/A